Oxybuprocaine
DERMATOLOGICALS
Also known as: benoxinate, benoxinate HCl, benoxinate hydrochloride, oxybucaine
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Oxybuprocaine is an ofp drug catalogued in DrugCentral. It was first approved by the FDA in 2020. DrugCentral lists 2 molecular targets, including SCN1A|SCN2A|SCN3A and SCN10A. Recorded indications include Topical local anesthetic to eye.
- Approval status: ofp (first approved 2020 by the FDA).
- Molecular targets: SCN1A|SCN2A|SCN3A and SCN10A (2 listed in DrugCentral).
- Indications: Topical local anesthetic to eye.
- ATC code: D04AB03 (Anesthetics for topical use).
- Molecular formula: C17H28N2O3; molecular weight 308.42 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Topical local anesthetic to eye
Mechanism & targets
Molecular targets (2)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Sodium channel alpha subunits; brain (Types I, II, III) | SCN1A|SCN2A|SCN3A | blocker | IC50 5.54 |
| Sodium channel protein type 10 subunit alpha | SCN10A | blocker | — |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2020-03-09 | FDA | — | BAUSCH |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
D04AB03 | DERMATOLOGICALS › ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. › ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. › Anesthetics for topical use |
S01HA02 | SENSORY ORGANS › OPHTHALMOLOGICALS › LOCAL ANESTHETICS › Local anesthetics |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Toxic anterior segment syndrome | 308.0 |
| Aqueous fibrin | 177.5 |
| Non-infectious endophthalmitis | 122.5 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Oxybuprocaine is on its molecule page.
| Molecular formula | C17H28N2O3 |
|---|---|
| Molecular weight | 308.42 g/mol |
| CAS number | 99-43-4 |
| InChIKey | CMHHMUWAYWTMGS-UHFFFAOYSA-N |
| PubChem CID | 4633 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Oxybuprocaine used for?
DrugCentral lists the following indications for Oxybuprocaine: Topical local anesthetic to eye.
How does Oxybuprocaine work?
Its molecular targets in DrugCentral include SCN1A|SCN2A|SCN3A (blocker) and SCN10A (blocker).
When was Oxybuprocaine first approved?
Oxybuprocaine was first approved by the FDA in 2020.
What is the chemical formula of Oxybuprocaine?
Oxybuprocaine has the molecular formula C17H28N2O3 and a molecular weight of 308.42 g/mol.
Browse: all drugs starting with O · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 3016 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1200 — compound record and bioactivity
- PubChem CID 4633 — chemical identifiers
- DrugBank DB00892 — drug record
- FDA UNII AXQ0JYM303 — substance identity
- DailyMed: FDA labels for Oxybuprocaine — current prescribing information (label search)
- UniProt Q9Y5Y9 (SCN10A) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.